Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BF-Amlodipine vs Norvasc
NCT02707913Phase 1Completed
- Sponsor
- Bright Future Pharmaceutical Laboratories Limited
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of amlodipine in hypertension (HTN) (2 arms), sponsored by Bright Future Pharmaceutical Laboratories Limited. Primary endpoints: Peak Plasma Concentration at 96 hours and Area Under the Curve at 96 hours. Started Mar 2016; status: completed.
02
Drugs
amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02707913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707913.